Trials / Completed
CompletedNCT02453334
Can Iron Lessen Anemia Due to Cancer and Chemotherapy: A Study to Investigate the Efficacy and Safety of Injectafer®
IRON CLAD: Can Iron Lessen Anemia Due to Cancer and Chemotherapy: A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injectafer® (Ferric Carboxymaltose Injection) in Adults
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 244 (actual)
- Sponsor
- American Regent, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Phase III, multicenter, randomized, double-blinded, prospective study with two parallel treatment groups. Patients who present to the hematologist/oncologist and satisfy all inclusion and exclusion criteria will be eligible for participation in this 18-week study.
Detailed description
This is a Phase III, multicenter, randomized, double-blinded, prospective study with two parallel treatment groups. Patients who present to the hematologist/oncologist and satisfy all inclusion and exclusion criteria will be eligible for participation in this 18-week study. Subjects who meet all inclusion criteria and no exclusion criteria, will be randomized into the trial (Group A or B).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Injectafer | |
| OTHER | Normal Saline |
Timeline
- Start date
- 2015-05-23
- Primary completion
- 2018-01-01
- Completion
- 2018-01-04
- First posted
- 2015-05-25
- Last updated
- 2021-05-11
- Results posted
- 2021-05-10
Locations
29 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02453334. Inclusion in this directory is not an endorsement.